CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
CareDx (CDNA) reported preliminary Q4 2024 results with expected revenue between $85-86 million, representing a 30% year-over-year increase. Testing services revenue is anticipated at $62.5-63.5 million, up 35% YoY, with testing volume reaching 45,500, a 14% increase.
For full-year 2024, revenue is expected to be $332-333 million, with Digital Solutions and Products each contributing $11.4 million. The company projects a GAAP loss of $58-60 million, but expects adjusted EBITDA gain of $25-26 million. Cash position strengthened to approximately $261 million, up $26 million YoY.
Looking ahead, CareDx provides 2025 revenue guidance of $370 million and maintains its 2027 targets of $500 million in revenue with 20% adjusted EBITDA. The company completed its sales and marketing team expansion with approximately 30 new professionals.
CareDx (CDNA) ha riportato risultati preliminari per il quarto trimestre del 2024 con un fatturato atteso compreso tra 85 e 86 milioni di dollari, rappresentando un incremento del 30% rispetto all'anno precedente. Si prevede che il fatturato dai servizi di test sia compreso tra 62,5 e 63,5 milioni di dollari, con un incremento del 35% rispetto all'anno scorso, e un volume di test che raggiunge 45.500, con un aumento del 14%.
Per l'intero anno 2024, il fatturato è previsto tra 332 e 333 milioni di dollari, con Soluzioni Digitali e Prodotti che contribuiscono ciascuno con 11,4 milioni di dollari. L'azienda prevede una perdita GAAP tra 58 e 60 milioni di dollari, ma si aspetta un guadagno di EBITDA rettificato tra 25 e 26 milioni di dollari. La posizione di cassa è rinforzata a circa 261 milioni di dollari, in aumento di 26 milioni di dollari rispetto all'anno precedente.
Guardando al futuro, CareDx fornisce una guida ai ricavi per il 2025 di 370 milioni di dollari e mantiene i suoi obiettivi del 2027 di 500 milioni di dollari di fatturato con un EBITDA rettificato del 20%. L'azienda ha completato l'espansione del proprio team vendite e marketing con circa 30 nuovi professionisti.
CareDx (CDNA) reportó resultados preliminares del cuarto trimestre de 2024 con ingresos esperados entre 85 y 86 millones de dólares, lo que representa un incremento del 30% interanual. Se anticipa que los ingresos por servicios de pruebas alcancen entre 62,5 y 63,5 millones de dólares, un aumento del 35% con respecto al año anterior, con un volumen de pruebas que alcanza 45.500, un incremento del 14%.
Para todo el año 2024, se espera que los ingresos sean de 332 a 333 millones de dólares, con Soluciones Digitales y Productos contribuyendo cada uno con 11,4 millones de dólares. La empresa proyecta una pérdida GAAP de entre 58 y 60 millones de dólares, pero espera un aumento del EBITDA ajustado de entre 25 y 26 millones de dólares. La posición de efectivo se fortaleció hasta aproximadamente 261 millones de dólares, un aumento de 26 millones de dólares interanual.
Mirando hacia el futuro, CareDx proporciona una guía de ingresos para 2025 de 370 millones de dólares y mantiene sus objetivos de 2027 de 500 millones de dólares en ingresos con un EBITDA ajustado del 20%. La empresa ha completado la expansión de su equipo de ventas y marketing con aproximadamente 30 nuevos profesionales.
CareDx (CDNA)는 2024년 4분기 예비 결과를 보고하며 예상 수익이 8천5백만에서 8천6백만 달러 사이에 이를 것으로 예상하며, 이는 전년 대비 30% 증가를 나타냅니다. 테스트 서비스 수익은 6천2백50만에서 6천3백50만 달러로 예상되며, 이는 전년 대비 35% 증가했으며, 테스트량은 45,500건으로 14% 증가할 것으로 예상됩니다.
2024년 전체 연도에 대해, 수익은 3억3천2백만에서 3억3천3백만 달러로 예상되며, 디지털 솔루션 및 제품은 각각 1천1백40만 달러를 기여할 것으로 보입니다. 회사는 GAAP 손실이 5천8백만에서 6천만 달러가 될 것으로 예상되지만, 조정된 EBITDA로 2천5백만에서 2천6백만 달러의 이익을 예상하고 있습니다. 현금 보유액은 약 2억6천1백만 달러로 증가했으며, 이는 전년 대비 2천6백만 달러 증가한 수치입니다.
앞을 내다보며, CareDx는 2025년 수익 가이드를 3억7천만 달러로 제공하고 있으며, 2027년에는 5억 달러의 수익 목표를 유지하고 조정된 EBITDA 20%를 목표로 하고 있습니다. 이 회사는 약 30명의 새로운 전문가를 추가하여 영업 및 마케팅 팀의 확장을 완료했습니다.
CareDx (CDNA) a annoncé des résultats préliminaires pour le quatrième trimestre 2024 avec un chiffre d'affaires attendu entre 85 et 86 millions de dollars, ce qui représente une augmentation de 30% par rapport à l'année précédente. Les revenus des services d'essai devraient atteindre entre 62,5 et 63,5 millions de dollars, en hausse de 35% d'une année sur l'autre, avec un volume de tests atteignant 45 500, soit une augmentation de 14%.
Pour l'année entière 2024, le chiffre d'affaires devrait se situer entre 332 et 333 millions de dollars, avec des Solutions et Produits Numériques contribuant chacun à hauteur de 11,4 millions de dollars. L'entreprise prévoit une perte GAAP entre 58 et 60 millions de dollars, mais s'attend à un gain d'EBITDA ajusté entre 25 et 26 millions de dollars. La position de trésorerie s'est renforcée pour atteindre environ 261 millions de dollars, en hausse de 26 millions de dollars par rapport à l'année précédente.
En regardant vers l'avenir, CareDx fournit des prévisions de revenus pour 2025 de 370 millions de dollars et maintient ses objectifs de 2027 de 500 millions de dollars de revenus avec un EBITDA ajusté de 20%. L'entreprise a terminé l'expansion de son équipe de vente et de marketing avec environ 30 nouveaux professionnels.
CareDx (CDNA) berichtete über vorläufige Ergebnisse für das vierte Quartal 2024 mit erwarteten Einnahmen zwischen 85 und 86 Millionen Dollar, was einen Anstieg von 30% im Vergleich zum Vorjahr darstellt. Der Umsatz aus Testdienstleistungen wird auf 62,5 bis 63,5 Millionen Dollar geschätzt, was einem Anstieg von 35% im Vergleich zum Vorjahr entspricht, mit einem Testvolumen von 45.500, was einem Anstieg von 14% entspricht.
Für das gesamte Jahr 2024 wird mit Einnahmen von 332 bis 333 Millionen Dollar gerechnet, wobei Digitale Lösungen und Produkte jeweils 11,4 Millionen Dollar beitragen. Das Unternehmen rechnet mit einem GAAP-Verlust zwischen 58 und 60 Millionen Dollar, erwartet jedoch einen bereinigten EBITDA-Gewinn von 25 bis 26 Millionen Dollar. Die Liquiditätsposition hat sich auf etwa 261 Millionen Dollar verbessert, ein Anstieg um 26 Millionen Dollar im Vergleich zum Vorjahr.
Für die Zukunft gibt CareDx eine Umsatzprognose von 370 Millionen Dollar für 2025 aus und hält an den Zielen von 500 Millionen Dollar Umsatz für 2027 mit einem bereinigten EBITDA von 20% fest. Das Unternehmen hat die Expansion seines Vertriebs- und Marketingteams mit rund 30 neuen Fachleuten abgeschlossen.
- Revenue growth of 30% YoY in Q4 2024
- Testing services revenue increased 35% YoY
- Testing volume up 14% YoY to 45,500
- Cash position improved by $26M YoY to $261M
- Positive adjusted EBITDA of $25-26M for 2024
- Six consecutive quarters of testing services volume growth
- Expected GAAP loss of $58-60M for 2024
- Q4 2024 GAAP loss of $32-34M
Insights
The Q4 2024 preliminary results showcase remarkable financial performance with revenue expected at
The forward guidance of
For retail investors: Think of CareDx as a specialized healthcare diagnostics company that's successfully converting market leadership into financial growth. The positive adjusted EBITDA despite GAAP losses is like a startup that's investing heavily in growth while maintaining healthy core operations.
The transplant diagnostics market dynamics strongly favor CareDx's positioning. The
The sales force expansion aligns with market opportunity timing, as transplant centers increasingly adopt molecular surveillance protocols. The company's strategic focus on kidney surveillance testing taps into the largest segment of the transplant diagnostics market, with significant growth potential given the rising transplant procedures globally.
Simple explanation: CareDx is like a specialized medical testing company that's growing because more hospitals are using their tests to monitor transplant patients. They're hiring more salespeople to reach more hospitals and their different types of services help them make money in multiple ways.
Fourth Quarter Revenue is Expected to Increase
Expects Full Year 2024 Revenue of
Preliminary Fourth Quarter 2024 Financial Results
-
Revenue is expected to be between
$85 million $86 million 30% year-over-year. -
Testing services revenue is expected to be between
$62.5 million $63.5 million 35% year-over-year. -
Testing Services volume of approximately 45,500 increased
14% year-over-year. -
Revenue is expected to be
$11.4 million $11.4 million -
GAAP loss is expected to be approximately
$32 million $34 million $8 million $9 million
Preliminary Full Year 2024 Financial Results
-
2024 revenue is expected to be between
$332 million $333 million -
2024 GAAP loss is expected to be between
$58 million $60 million $25 million $26 million -
Cash, cash equivalents, and marketable securities as of December 31, 2024, is expected to be approximately
$261 million $26 million
2025 Revenue Guidance
-
CareDx anticipates revenue of
$370 million
“Continuing our mission to serve transplant patients, we achieved our sixth consecutive quarter of testing services volume growth in the fourth quarter. Momentum continued to build for kidney surveillance testing throughout the quarter, and we completed our sales and marketing expansion by about 30 professionals. We are well-positioned for another successful year of growth in 2025 and on pace to achieve our targets of
The preliminary financial information presented in this press release is based on CareDx’s current expectations and may be adjusted as a result of, among other things, the completion of customary annual audit procedures. CareDx will report on the fourth quarter and full year 2024 financial results and anticipates providing 2025 financial guidance on its February 2025 earnings call.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in
Forward Looking Statements
This press release includes forward-looking statements, including expectations regarding CareDx’s fourth quarter and full year 2024 revenue, other fourth quarter and full year 2024 GAAP and non-GAAP results, number of patient results, and cash, cash equivalents, and marketable securities as of December 31, 2024, achievement of its financial and operational goals, its prospects in 2025, its 2027 revenue and adjusted EBITDA targets, and its anticipation to report 2024 financial results and provide 2025 financial guidance on its February 2025 earnings call. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties that could cause the actual results to differ materially from those projected, including the completion of the audit of CareDx’s 2024 financial statements, general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the quarterly report on Form 10-Q for the quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024, the quarterly report on Form 10-Q for the quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, the quarterly report on Form 10-Q for the quarter ended September 30, 2024 filed by CareDx with the SEC on November 4, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
CareDx, Inc. |
|||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||
(Unaudited and Preliminary) |
|||||||
(In thousands) |
|||||||
|
2024 |
||||||
|
Three Months Ended December 31 |
Twelve Months Ended December 31 |
|||||
GAAP net loss |
$ |
(33,300 |
) |
$ |
(58,800 |
) |
|
Stock-based compensation expense |
|
39,600 |
|
|
79,800 |
|
|
Restructuring costs and charges |
|
1,700 |
|
|
1,800 |
|
|
Acquisition related-amortization of purchased intangibles |
|
1,500 |
|
|
6,300 |
|
|
Non-GAAP net income |
$ |
9,500 |
|
$ |
29,100 |
|
|
CareDx, Inc. |
|||||||
Reconciliation of Non-GAAP to Adjusted EBITDA |
|||||||
(Unaudited and Preliminary) |
|||||||
(In thousands) |
|||||||
|
2024 |
||||||
|
Three Months Ended December 31 |
Twelve Months Ended December 31 |
|||||
Non-GAAP net income |
$ |
9,500 |
|
$ |
29,100 |
|
|
Interest income |
|
(2,900 |
) |
|
(11,600 |
) |
|
Income tax expense |
|
100 |
|
|
100 |
|
|
Depreciation expense |
|
1,900 |
|
|
7,900 |
|
|
Other income, net |
|
(100 |
) |
|
— |
|
|
Adjusted EBITDA |
$ |
8,500 |
|
$ |
25,500 |
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113365494/en/
CareDx, Inc.
Media Relations
Anna Czene
818-731-2203
aczene@caredx.com
Investor Relations
Caroline Corner
investor@caredx.com
Source: CareDx, Inc.
FAQ
What is CareDx's expected revenue for Q4 2024?
How much cash does CDNA have as of December 31, 2024?
What is CDNA's revenue guidance for 2025?
What are CareDx's 2027 financial targets?
What was CDNA's testing services volume growth in Q4 2024?
